Target intelligence / Profile preview

Zyg-11 family member B, cell cycle regulator (ZYG11B)

Target
ZYG11B
Molecular classification
Substrate recognition subunit (SRS), Component of E3 ubiquitin ligase complex/CUL2-RING ubiquitin-ligase family, Protein quality control factor
01

Overview

Zyg-11 family member B, cell cycle regulator (ZYG11B) is a substrate recognition component of a CUL2-based E3 ubiquitin ligase complex, functioning primarily in the selective degradation of proteins bearing specific N-terminal degrons, which is critical for protein quality control, cell cycle progression, and the regulation of apoptosis. ZYG11B and its homologues interact with Elongin C and CUL2 via a conserved VHL-box motif, thereby forming a functional E3 ligase complex that modulates proteasomal degradation pathways. The biological activities of ZYG11B include facilitating timely cell cycle transitions, aiding in the removal of defective or misfolded proteins, clearing proteolytic fragments generated during apoptosis, and contributing to antiviral responses by enhancing the cGAS pathway. Human diseases associated with mutations in ZYG11B include craniofacial microsomia and familial hypertrophic cardiomyopathy; however, no drugs are currently known to target this molecule directly. It is considered an intracellular regulatory/protein quality control factor rather than a classical receptor or enzyme.

Other names
ZYG11BZYG11ZYGC9orf60ZYG11BLzyg-11 family member B, cell cycle regulator
02

Mechanism of action

As a substrate adapter in CUL2-based E3 ubiquitin ligase complexes, it promotes targeted degradation of proteins with specific N-terminal motifs (e.g., N-terminal glycine) by the proteasome ([targeting N-degron pathway])

03

Biological functions

Cell cycle regulationProtein ubiquitination and proteasomal degradationQuality control of N-myristoylationApoptosis (removal of caspase cleavage products)Amplification of innate immune response via cGAS pathway
04

Disease associations

Cancer (implicated based on protein quality control and cell cycle links, though specific roles are not well-established)Craniofacial microsomia 1Familial hypertrophic cardiomyopathy 26Potentially other disorders involving protein homeostasis and cell cycle
05

Safety considerations

Not well-documented, but given its role in protein homeostasis and cell cycle, hypothetical therapeutic targeting could impact essential cellular processes leading to unintended cytotoxicity or cell cycle arrest
06

Interacting drugs

None specifically identified in current databases and published literature
07

Biomarkers

None established for patient selection or efficacy monitoring as of current knowledge

Beyond the preview

Go deeper on Zyg-11 family member B, cell cycle regulator (ZYG11B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zyg-11 family member B, cell cycle regulator (ZYG11B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call